Search

Displaying results 4461 - 4470 of 10000 in total
  1. Drug

    ISIS 14803

    go.drugbank.com/drugs/DB05803
    Investigational

    protein expression in cell culture. … ISIS 14803 is a 20-unit antisense phosphorothioate oligodeoxynucleotide that binds to hepatitis C virus (HCV) RNA at the translation initiation region of the internal ribosome entry site (IRES) and inhibits

  2. Drug

    Tariquidar

    go.drugbank.com/drugs/DB06240
    Investigational

  3. Drug

    PYM50018

    go.drugbank.com/drugs/DB05126
    Experimental

    In pre-clinical models, PYM50018 has been observed to protect against neuronal damage, increase neurite outgrowth, reverse oxidative damage and reverse neuronal apoptosis in vitro. … PYM50018 is a patented, orally active, neuroprotective and neuroregenerative compound. It is developed for the treatment of amyotrophic lateral sclerosis (ALS, also known as Lou Gehrig's disease).

  4. Drug

    Brecanavir

    go.drugbank.com/drugs/DB04887
    Investigational

    In July 2006, Vertex indicated that it expected GSK to initiate phase III trials of the drug in 2007. … In December of 2006 GSK announced a decision to discontinue the development of brecanavir for the treatment of HIV. The decision was based on issues regarding the formulation of the drug.

  5. Drug

    Quinestrol

    go.drugbank.com/drugs/DB04575
    Approved

    The 3-cyclopentyl ether of ethinyl estradiol.

  6. Drug

    Eprotirome

    go.drugbank.com/drugs/DB05035
    Investigational

    Eprotirome which is a compound with promising properties for treatment of obesity and dyslipidemia.

  7. Drug

    Arbaclofen

    go.drugbank.com/drugs/DB08891
    Investigational

    It is believed to be a selective gamma-amino butyric acid type B receptor agonist, and has been investigated as a treatment for autism spectrum disorder and fragile X syndrome in randomized, double blind … Arbaclofen, or STX209, is the R-enantiomer of baclofen.

  8. Drug

    ISIS 113715

    go.drugbank.com/drugs/DB05506
    Investigational

    In early trials, ISIS 113715 induced statistically significant improvements in multiple measures of glucose control along with statistically significant reductions in LDL-cholesterol. … ISIS 113715 is our second-generation antisense inhibitor of protein tyrosine phosphatase 1b, or PTP‑1b, for the treatment of type 2 diabetes.

  9. Drug

    Fasinumab

    go.drugbank.com/drugs/DB12157
    Investigational

    [A241190] It has since been recognized for its role in nociceptive signaling transduction and has thus become an attractive target in the treatment of chronic pain conditions. … NSAIDs and/or opioids) in this patient population.[A241165] NGF was first discovered in the 1950s[A241180] and was the first neurotrophic factor to be identified and biochemically characterized.

  10. Drug

    Epicept NP-1

    go.drugbank.com/drugs/DB05492
    Investigational

    Peripheral neuropathies are medical conditions caused by damage to the nerves in the peripheral nervous system. … EpiCept NP-1 Cream is a patented formulation containing two FDA-approved drugs, amitriptyline (a widely-used antidepressant) and ketamine (an NMDA antagonist that is used as an anesthetic).